Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Chemical modification or the reaction product thereof – e.g.,...
Reexamination Certificate
1997-03-10
2003-04-15
Low, Christopher S. F. (Department: 1653)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Chemical modification or the reaction product thereof, e.g.,...
C530S334000, C530S337000, C530S389200, C530S391700, C530S409000, C530S410000, C530S810000, C424S143100, C424S146100, C424S178100, C424S182100
Reexamination Certificate
active
06548644
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to processes for modifying proteins. More particularly, the present invention involves processes for linking polyethylene glycol to proteins in a manner which provides advantages associated with polyethylene glycol conjugated proteins while maintaining a desired protein bioactivity.
2. Description of Related Art
Processes and reagents for chemically modifying proteins have been used extensively for decades. Traditionally, protein chemical modifications were carried out in order to study their functional properties and structural characteristics. With the emergence of recombinant DNA techniques and protein therapeutics, researchers have chemically modified proteins to alter their therapeutic properties. In particular, processes for conjugating proteins with polyethylene glycol have gained widespread use within the pharmaceutical and biochemical communities as a result of numerous improved pharmacological and biological properties associated with polyethylene glycol conjugated proteins. For example, polyethylene glycol modification is known to extend significantly the plasma half life of proteins used in clinical applications, thus substantially improving the clinical usefulness of the protein. Polyethylene glycol conjugation also is known to reduce the antigenicity and immunogenicity of proteins, thereby reducing life-threatening anaphylaxis.
Another benefit associated with polyethylene glycol modified proteins is that water solubility which is increased as a result of the high water solubility of polyethylene glycol. The increased water solubility can improve the protein's formulation characteristics at physiological pH's and can decrease complications associated with aggregation of low solubility proteins.
Additionally, polyethylene glycol conjugated proteins have found use in bioindustrial applications such as enzyme based reactions in which the reaction environment is not optimal for the enzyme's activity. For example, some polyethylene glycol conjugated enzymes demonstrate a wider optimum pH activity and reduced optimum activity temperature. Moreover, enzymes having reduced activity in many organic solvents have been successfully conjugated with polyethylene glycol to a degree that renders them useful for catalyzing reactions in organic solvents. For example, polyethylene glycol has been conjugated with horseradish peroxidase which then becomes soluble and active in chloroform and toluene (Urrotigoity et al.,
Biocatalysis
, 2:145-149, 1989).
Polyethylene glycol conjugated proteins vary in the extent to which plasma circulation half life is increased, immunogenicity is reduced, water solubility is enhanced, and enzymatic acitivity is improved. Factors responsible for these variations are numerous and include the degree to which the protein is substituted with polyethylene glycol, the chemistries used to attach the polyethylene glycol to the protein, and the locations of the polyethylene glycol sites on the protein.
The most common methods for attaching polyethylene glycol to proteins involve activating at least one of the hydroxyl groups on the polyethylene glycol with a functionality susceptible to nucleophilic attack by the nitrogen of amino groups on the protein. These methods generally result in loss of biological activity due to the nonspecific attachment of polyethylene glycol
Alternative approaches to conjugating proteins with polyethylene glycol include controlling the conjugation reactants and conditions so that the conjugation site is confined to the N-terminus (Kinstler et al.
Pharm. Res
. 13:996, 1996) attaching polyethylene glycol to protein carbohydrate functionalities (Urrutigoity, et al.
Biocatalysis
2:145, 1989) and attaching polyethylene glycol at protein cysteine residues (Goodson et al.
Biotechnology
8:343, 1990). While these offer some degree of control of the reaction site, there is a continuing need for improved methods for providing polyethylene glycol conjugated proteins. In particular, it would be desirable to provide methods for conjugating proteins with polyethylene glycol that result in modified proteins having enhanced bioactivity or little loss in bioactivity while maintaining the benefits of polyethylene glycol conjugation, including substantially decreased immunogenicity, increased solubility, and prolonged circulation half lives characteristic of modified proteins.
SUMMARY OF THE INVENTION
The present invention provides protein modification processes that result in modified proteins having little or no decrease in an activity associated with the protein. More particularly, the invention described herein includes processes for modifying a protein by first protecting a site on the protein and then contacting the protected protein with polyethylene glycol under conditions suitable for linking the polyethylene glycol to the protein. After deprotecting the protein, the resulting polyethylene glycol modified protein has improved characteristics over proteins modified according to prior art procedures. An advantageous retention of activity is attributed to the availability of one or more protein binding sites which is unaltered in the conjugation process and thus remains sterically free to interact with a binding partner subsequent to the conjugation process.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 5235028 (1993-08-01), Barany et al.
patent: 5514572 (1996-05-01), Veronese et al.
patent: WO 94/13322 (1994-06-01), None
patent: WO 94/20069 (1994-09-01), None
patent: WO 96/11213 (1996-04-01), None
Delgado et al., Critical Reviews in Therapeutic Drug Carrier Systems, 9(3,4), pp. 249-304, 1992.*
Mohler et al.,J. Immunol.,vol. 151, No. 3, pp. 1548-1561, Aug. 1993.*
Paul, W.F. (ed.),Fundamental Immunology, 3rdeddition, pp. 807-812, 1993.*
Ware et al.,Immunology, vol. 147, p. 4229.*
Goodson et al.,Bio/Technology, vol. 8, pp. 343-346, Apr. 1990.*
Pettit et al,The Journal of Biological Chemistry, vol. 272, No. 4, pp. 2312-2318, Jan. 24.*
Lu et al,Int. J. Peptide Protein Res, vol. 43, pp. 127-138, 1994.*
Pettit et al,Polymer Prepr(Am. Chem. Soc. Div. Polym. Chem), vol. 38, No. 1, pp. 574-575, Apr. 1997.*
Mohler et al., “Soluble Tumor Necrosis Factor (TNF) Receptors are Effective Therapeutic Agents in Lethal Endotoxemia and Function Simultaneously as Both TNF Carriers and TNF Antagonists”,The Journal of Immunology 151:548-1561, 1993.
Onozaki et al., “Human Interleukin 1 is a Cytocidal Factor for Several Tumor Cell Lines”,The Journal of Immunology 135:3962-68, Dec. 1985.
Sartore et al., “Accurate Evaluation Method of the Polymer Content in Monomethoxy (Polyethylene Glycol) Modified Proteins Based on Amino Acid Analysis”,Applied Biochemistry and Biotechnology 31:213-222, 1991.
Goodson et al., “Site-Directed Pegylation of Recombinant Interleukin-2 at its Glycosylation Site”,Bio/Technology 8:343-46, Apr. 1990.
Kinstler et al., “Characterization and Stability of N-terminally PEGylated rhG-CSF”,Pharmaceutical Research 13:996-1002, 1996.
Gombotz et al., “Biodegradable Polymers for Protein and Peptide Drug Delivery”,Bioconjugate Chemistry 6:332-351, 1995.
Pettit et al., “Structure-Function Studies of Interleukin 15 using Site-specific Mutagenesis, Polyethylene Glycol Conjugation, and Homology Modeling”,The Journal of Biological Chemistry 272:2312-2318, 1997.
Urrutigoity et al., “Biocatalysis in Organic Solvents with a Polymer-Bound Horseradish Peroxidase”,Biocatalysis 2:145-149, 1989.
Delgado et al., “The Uses and Properties of PEG-Linked Proteins”,Critical Reviews in Therapeutic Drug Carrier Systems 9:249-304, 1992.
Paul, W.F. (ed), Fundamental Immunology, 3rd edition, pp. 807-812.
Henry Janis C.
Immunex Corporation
Low Christopher S. F.
Mohamed Abdel A.
LandOfFree
Site protected protein modification does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Site protected protein modification, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Site protected protein modification will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3048934